Efficiency of Bumetanide in Autistic Children

Last updated: December 20, 2011
Sponsor: University Hospital, Brest
Overall Status: Completed

Phase

3

Condition

Autism

Autism Spectrum Disorder (Asd)

Treatment

N/A

Clinical Study ID

NCT01078714
RB09-017
  • Ages 3-10
  • All Genders

Study Summary

The purpose of this study is to determine if a treatment by bumetanide presents an efficiency at the level of the neuronal maturation in the autism

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Children from 3 to 10 years old, answering the diagnosis of typical autism accordingto the diagnostic criteria of autism of the classification of the WHO ( CIM-10) andthe parents of which gave a free, enlightened and written consent.

Exclusion

Exclusion Criteria:

  • Patients epileptic autistics treated by anticomitiaux or having hurts of the centralnervous system

  • Patients autistics receiving a psychotropic treatment

  • Patients presenting disorders electrolytes

  • Patients presenting a hypersensibility known about sulpha drugs

  • Presenting patients against indications relative to the treatment by bumetanide

  • Patients already treated by diuretics

  • Patients presenting a hepatic or renal incapacity

  • Patients presenting an elongation of the QT to the electrocardiogram.

  • Patients autistics of CARS sore is lower than 30.

Study Design

Total Participants: 60
Study Start date:
March 01, 2010
Estimated Completion Date:
June 30, 2011

Connect with a study center

  • Lemonnier

    Brest, 29609
    France

    Site Not Available

  • Chevreuil

    Rennes, 35703
    France

    Site Not Available

  • DUPIN

    Vannes, 56000
    France

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.